Compare AbbVie Inc (ABBV) vs iShares Global Tech ETF (IXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares Global Tech ETF — how do they compare? AbbVie Inc trades at $254.02 (market cap $449.91B), while iShares Global Tech ETF trades at $134. The key difference: AbbVie Inc pays a 2.72% dividend while iShares Global Tech ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares Global Tech ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | IXN | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $149.74 |
52-Week Low | $184.85 | $92.92 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.76, down 2.42% on the day, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company demonstrates solid fundamental performance with Q1 2026 earnings beating expectations at $2.65 EPS versus $2.59 expected, continuing a trend of quarterly beats. Revenue growth remains robust at $61.16 billion for 2025, supported by successful portfolio transition beyond Humira patent expiration.
AbbVie presents a compelling investment case with 68% analyst buy ratings and a $266.33 consensus target offering 4.5% upside. Key opportunities include Skyrizi and Rinvoq driving growth, while risks involve patent cliffs in the 2030s and high valuation multiples. The company's dividend aristocrat status and strong cash flow generation support continued shareholder returns.
IXN trades at $139.47, up 2.18% on the day, with a neutral technical signal overall. The ETF's technical indicators show mixed signals, with moving averages bearish and oscillators neutral. Recent news highlights its strong global tech exposure but notes high valuations and concentration risks. No recent financial statements or cash flow data are provided in the context for the current period.
The outlook for IXN is cautious due to stretched valuations and high expectations, with sentiment divided among analysts. Key risks include tech sector volatility and dependence on AI-driven growth. Investors should weigh the ETF's tech leadership against valuation concerns before making decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →
